Company Summary: Kairos Pharma, Ltd.

Overview:
Kairos Pharma, Ltd. is a biotechnology company primarily involved in licensing and developing innovative therapies for cancer, autoimmune diseases, fibrosis, and other conditions related to mitochondrial and genomic DNA depletion, tumor sensitization, and immune cell activation. The company holds multiple licensing agreements and patents related to these therapeutic areas, particularly in connection with technologies developed in collaboration with Cedars-Sinai Medical Center.

Business Focus:

• Licensing and developing pharmaceutical compounds and methods for treating cancer and autoimmune diseases.
• Developing therapies that involve depletion of mitochondrial or genomic DNA from circulation.
• Sensitization of solid tumors to enhance the effectiveness of existing therapies.
• Methods of generating activated T cells for cancer therapy.
• Treatment of fibrosis and other conditions through targeted molecular and cellular approaches.

Key Activities and Assets:

• The company’s operations are heavily based on licensing intellectual property, including multiple license and supply agreements with Cedars-Sinai Medical Center and other entities.
• Holds rights to various patents and license agreements for methods and compounds in oncology and immunology.
• The company is also involved in issuing convertible notes and securities, as well as employing a stock incentive plan.

Employees, Customers, Revenue, and Income:

• As of April 14, 2025, the company had 16,693,306 shares of common stock outstanding.
• The document does not provide specific details regarding the number of employees, total customers, revenue, or net income.
• There is no financial data or performance metrics explicitly included in the provided excerpt.

Additional Details:

• The company is classified as an "emerging growth company" and a smaller reporting company.
• It is not a well-known seasoned issuer, nor does it file reports under the Securities Exchange Act of 1934.
• The company’s headquarters is located at No. 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
• The company’s stock trades on the NYSE under the symbol KAPA.

Note:
This summary is based solely on the provided Form 10-K/A filing excerpt and does not include any additional or updated financial or operational data outside this document.